Literature DB >> 10029595

Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.

J S Damiano1, A E Cress, L A Hazlehurst, A A Shtil, W S Dalton.   

Abstract

Integrin-mediated adhesion influences cell survival and may prevent programmed cell death. Little is known about how drug-sensitive tumor cell lines survive initial exposures to cytotoxic drugs and eventually select for drug-resistant populations. Factors that allow for cell survival following acute cytotoxic drug exposure may differ from drug resistance mechanisms selected for by chronic drug exposure. We show here that drug-sensitive 8226 human myeloma cells, demonstrated to express both VLA-4 (alpha4beta1) and VLA-5 (alpha5beta1) integrin fibronectin (FN) receptors, are relatively resistant to the apoptotic effects of doxorubicin and melphalan when pre-adhered to FN and compared with cells grown in suspension. This cell adhesion mediated drug resistance, or CAM-DR, was not due to reduced drug accumulation or upregulation of anti-apoptotic Bcl-2 family members. As determined by flow cytometry, myeloma cell lines selected for drug resistance, with either doxorubicin or melphalan, overexpress VLA-4. Functional assays revealed a significant increase in alpha4-mediated cell adhesion in both drug-resistant variants compared with the drug-sensitive parent line. When removed from selection pressure, drug-resistant cell lines reverted to a drug sensitive and alpha4-low phenotype. Whether VLA-4-mediated FN adhesion offers a survival advantage over VLA-5-mediated adhesion remains to be determined. In conclusion, we have demonstrated that FN-mediated adhesion confers a survival advantage for myeloma cells acutely exposed to cytotoxic drugs by inhibiting drug-induced apoptosis. This finding may explain how some cells survive initial drug exposure and eventually express classical mechanisms of drug resistance such as MDR1 overexpression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10029595      PMCID: PMC5550098     

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  65 in total

1.  Cleavage of focal adhesion kinase by caspases during apoptosis.

Authors:  L P Wen; J A Fahrni; S Troie; J L Guan; K Orth; G D Rosen
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

2.  Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers.

Authors:  M R Abbaszadegan; A E Cress; B W Futscher; W T Bellamy; W S Dalton
Journal:  Cancer Res       Date:  1996-12-01       Impact factor: 12.701

3.  Regulation of Bcl-xL expression in human keratinocytes by cell-substratum adhesion and the epidermal growth factor receptor.

Authors:  U Rodeck; M Jost; J DuHadaway; C Kari; P J Jensen; B Risse; D L Ewert
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

4.  Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents.

Authors:  B St Croix; V A Flørenes; J W Rak; M Flanagan; N Bhattacharya; J M Slingerland; R S Kerbel
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

5.  Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase.

Authors:  H C Chen; J L Guan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

6.  Functional evidence for three distinct and independently inhibitable adhesion activities mediated by the human integrin VLA-4. Correlation with distinct alpha 4 epitopes.

Authors:  R Pulido; M J Elices; M R Campanero; L Osborn; S Schiffer; A García-Pardo; R Lobb; M E Hemler; F Sánchez-Madrid
Journal:  J Biol Chem       Date:  1991-06-05       Impact factor: 5.157

7.  Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens.

Authors:  B W Futscher; L L Blake; J H Gerlach; T M Grogan; W S Dalton
Journal:  Anal Biochem       Date:  1993-09       Impact factor: 3.365

8.  High plasma fibronectin levels in multiple myeloma patients: possible mechanisms and clinical implications.

Authors:  M Paizi; J Manaster; M Quitt; G Spira
Journal:  Scand J Immunol       Date:  1991-09       Impact factor: 3.487

9.  Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells.

Authors:  G Koopman; R M Keehnen; E Lindhout; W Newman; Y Shimizu; G A van Seventer; C de Groot; S T Pals
Journal:  J Immunol       Date:  1994-04-15       Impact factor: 5.422

10.  Antimetastatic effect by anti-adhesion therapy with cell-adhesive peptide of fibronectin in combination with anticancer drugs.

Authors:  I Saiki; J Yoneda; H Kobayashi; Y Igarashi; H Komazawa; Y Ishizaki; I Kato; I Azuma
Journal:  Jpn J Cancer Res       Date:  1993-03
View more
  265 in total

1.  Establishment of an HS23 stromal cell-dependent myeloma cell line: fibronectin and IL-6 are critical.

Authors:  Akira Sakai; Miyo Oda; Mitsuhiro Itagaki; Noriaki Yoshida; Koji Arihiro; Akiro Kimura
Journal:  Int J Hematol       Date:  2010-10-06       Impact factor: 2.490

2.  The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin.

Authors:  Osvaldo Pontiggia; Rocio Sampayo; Diego Raffo; Andrea Motter; Ren Xu; Mina J Bissell; Elisa Bal de Kier Joffé; Marina Simian
Journal:  Breast Cancer Res Treat       Date:  2011-09-21       Impact factor: 4.872

Review 3.  Integrin signalling and the cellular response to ionizing radiation.

Authors:  Nils Cordes; Viktor Meineke
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

4.  Microenvironment: Neighbourhood watch.

Authors:  Virginia Hughes
Journal:  Nature       Date:  2011-12-14       Impact factor: 49.962

5.  Myeloma as a model for the process of metastasis: implications for therapy.

Authors:  Irene M Ghobrial
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

Review 6.  Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Authors:  Michaela R Reagan; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

7.  Sam68 regulates cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) via the AKT pathway in non-Hodgkin's lymphoma.

Authors:  Yaxun Wu; Xiaohong Xu; Xiaobing Miao; Xinghua Zhu; Haibing Yin; Yunhua He; Chunsun Li; Yushan Liu; Yali Chen; Xiaoyun Lu; Yuchan Wang; Song He
Journal:  Cell Prolif       Date:  2015-10-19       Impact factor: 6.831

8.  Ancient hot and cold genes and chemotherapy resistance emergence.

Authors:  Amy Wu; Qiucen Zhang; Guillaume Lambert; Zayar Khin; Robert A Gatenby; Hyunsung John Kim; Nader Pourmand; Kimberly Bussey; Paul C W Davies; James C Sturm; Robert H Austin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-03       Impact factor: 11.205

9.  MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma.

Authors:  Anthony W Gebhard; Priyesh Jain; Rajesh R Nair; Michael F Emmons; Raul F Argilagos; John M Koomen; Mark L McLaughlin; Lori A Hazlehurst
Journal:  Mol Cancer Ther       Date:  2013-09-18       Impact factor: 6.261

10.  Apoptotic death of hematopoietic tumor cells through potentiated and sustained adhesion to fibronectin via VLA-4.

Authors:  Yohei Saito; Toshiyuki Owaki; Takuya Matsunaga; Mizue Saze; Shogo Miura; Mao Maeda; Mayu Eguchi; Rika Tanaka; Junichi Taira; Hiroaki Kodama; Sumio Goto; Yoshiroh Niitsu; Hiroshi Terada; Fumio Fukai
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.